IgGenix, Inc

IgGenix, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2019 by a team of distinguished scientists.

The company focuses on developing innovative therapeutic solutions for allergic diseases, particularly food allergies like peanut allergy and environmental allergies. IgGenix aims to fill a significant gap in allergy treatment by creating therapies that provide faster and more sustained clinical responses. The company's core technology is the SEQ SIFTERTM antibody discovery platform, which utilizes single-cell genomic technology to isolate and engineer allergen-specific antibodies. Its lead product candidate, IGNX001, is a therapeutic IgG4 monoclonal antibody designed to suppress allergen-triggered immunity and block allergic reactions. IgGenix has successfully raised approximately $75 million in funding to advance its pipeline, which also includes therapies for other severe food and environmental allergies. The company targets patients with severe allergies, healthcare providers, and potential pharmaceutical partners for collaboration in developing and commercializing its therapies.